Miami, FL, June 26, 2018 --(PR.com
)-- Gensco Pharma announces the availability of ColciGel®, a prescription transdermal gel that provides relief of acute gout flares utilizing patented transdermal technology, is available through national retail chain pharmacies nationwide.
Gout, an extremely painful form of inflammatory arthritis, affects more than 4 percent of Americans between 40 and 60 years of age and about 10 percent of men over the age of 60. The disease occurs due to an excess of the bodily waste, uric acid. The acid is deposited as needle-like crystals in the joints or in soft tissue. These crystals cause redness, swelling, stiffness and intense pain in the joints which in turn create gout flares.
“Unfortunately, gout attacks occur suddenly, without warning. This sudden attack is referred to as a 'flare'. The flare will normally subside within 3-10 days but during that timeframe, the patient is in excruciating pain if untreated and unable to perform many daily functions,” said Gary Myerson, M.D., Founding Fellow of the American College of Rheumatology. “The secret to the treatment of the acute gout attack is to be prepared and treat the flare early.”
Gensco Pharma, a specialty pharmaceutical company focusing on research, development and marketing of transdermal prescription products, has developed a transdermal colchicine gel to treat these sudden flare-ups. Patient experience with ColciGel® has yielded treatment results of rapid relief of pain within 3-48 hours. And, even more favorable, ColciGel® is proven to have negligible systemic absorption improving tolerability and minimizing side effects, interactions and comorbidities caused by oral colchicine and NSAIDs such as hepatic impairment, renal dysfunction and gastrointestinal issues.
Prescription ColciGel®, transdermal Colchicine, unlike colchicine pills, which are taken orally for gout, doesn’t produce the often-intolerable gastrointestinal side effects due to its toxicity. “The plant-based medication in ColciGel has been used as an anti-inflammatory treatment for ages, dating back to the Egyptian pharaohs and Native Americans. At the first onset of an attack, the gel is to be applied directly to the site of the pain,” Myerson says.
According to Dr. Myerson, approximately 50% of gout sufferers have co-morbid conditions, such as heart disease and diabetes, which makes treating gout with other medication problematic. “ColciGel® has zero side effects and is applied directly to the site of the gout flare. Though some people, mostly men, develop gout due to a genetic predisposition, ill-functioning kidneys, poor circulation and physical trauma to the foot, are other typical factors leading to gout,” Myerson states.
Gensco Pharma has created programs to ensure all gout sufferers can access ColciGel. Copay assistance and cash pay programs are available to all patients through participating retail pharmacies. “As a pharmaceutical manufacturer, we have a responsibility to provide access to safe and effective medications. We recognize the need to assist with the financial burden as our duty,” said Carlos Alfaras, CEO of Gensco Pharma. “Our blend of science and understanding of the value proposition to patients, physicians and industry partners drives us to develop improved outcomes for all. Improving access to products providing better quality of life for patients who suffer from pain and debilitating diseases is core to our company’s mission.”
ColciGel® is distributed through major wholesalers and is available at major national chain pharmacies including, but not limited to; Walgreens®, CVS, Publix and Walmart. ColciGel® is contracted with DAPA (Contract #SP0200-15-H-0003) and the Federal Supply Schedule (FSS), making it accessible to military personnel and is also available to MEDICARE patients (Medicare Contract #P1466). Copay assistance and cash pay voucher programs are available to all patients through participating pharmacies. For more information on ColciGel®, visit www.colcigel.com.
About Gensco Pharma: Gensco® Pharma is a specialty pharmaceutical company focusing on research, development and marketing of transdermal prescription products. As an innovator of pharmaceutical products, Gensco® Pharma currently manufactures non-narcotic transdermal analgesic gels utilizing our patented drug delivery solutions. Gensco® Pharma’s airless, closed-system, metered dose technology, MDose™, dispenses the exact amount of medication per application, yielding maximized results and minimized side effects. As a healthcare partner, Gensco® is in continual pursuit of novel and effective therapies designed to improve health. www.genscolabs.com